Back to results
US 2022/0031682 A1Published application
Sphingosine kinase 2 inhibitor for treating coronavirus infection
AssigneeRedHill Biopharma Ltd.
InventorsDror Ben-Asher, Reza Fathi
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Claims30
A method for the treatment of the 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus, comprising administering to a patient with moderate to severe COVID-19-related pneumonia an effective amount of ABC294640,
- as a free base or salt thereof.
A method of treatment comprising administering an effective amount of ABC294640,
- as a free base or salt thereof, to a patient with moderate to severe COVID-19-related pneumonia caused by the SARS-CoV-2 virus.
Dependencies are inferred from the claim text.